Toxicity and management in CAR T-cell therapy

被引：661

作者：

Bonifant, Challice L. ^{[1
]}

Jackson, Hollie J. ^{[2
]}

Brentjens, Renier J. ^{[2
]}

Curran, Kevin J. ^{[3
]}

机构：

[1] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA

来源：

MOLECULAR THERAPY-ONCOLYTICS | 2016年 / 3卷

关键词：

CYTOKINE-RELEASE SYNDROME; CHIMERIC ANTIGEN RECEPTORS; GENE-THERAPY; SUICIDE-GENE; RAPID EXPANSION; PHASE-I; LYMPHOCYTES; ACTIVATION; SAFETY; IMMUNOTHERAPY;

D O I：

10.1038/mto.2016.11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, "on target/off tumor" recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.

引用

页数：7

共 77 条

[1]

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].

Ahmed, Nabil ;

Brawley, Vita S. ;

Hegde, Meenakshi ;

Robertson, Catherine ;

Ghazi, Alexia ;

Gerken, Claudia ;

Liu, Enli ;

Dakhova, Olga ;

Ashoori, Aidin ;

Corder, Amanda ;

Gray, Tara ;

Wu, Meng-Fen ;

Liu, Hao ;

Hicks, John ;

Rainusso, Nino ;

Dotti, Gianpietro ;

Mei, Zhuyong ;

Grilley, Bambi ;

Gee, Adrian ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Wels, Winfried S. ;

Wang, Lisa L. ;

Anderson, Peter ;

Gottschalk, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+

[2]

Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity [J].

Ando, M. ;

Hoyos, V. ;

Yagyu, S. ;

Tao, W. ;

Ramos, C. A. ;

Dotti, G. ;

Brenner, M. K. ;

Bouchier-Hayes, L. .

CANCER GENE THERAPY, 2014, 21 (11) :472-482

[3]

[Anonymous], 2015, BLOOD, DOI DOI 10.1182/BLOOD.V126.23.683.683

[4]

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].

Bonini, C ;

Ferrari, G ;

Verzeletti, S ;

Servida, P ;

Zappone, E ;

Ruggieri, L ;

Ponzoni, M ;

Rossini, S ;

Mavilio, F ;

Traversari, C ;

Bordignon, C .

SCIENCE, 1997, 276 (5319) :1719-1724

[5]

TRANSFER OF THE HSV-TK GENE INTO DONOR PERIPHERAL-BLOOD LYMPHOCYTES FOR IN-VIVO MODULATION OF DONOR ANTITUMOR IMMUNITY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].

BORDIGNON, C ;

BONINI, C ;

VERZELETTI, S ;

NOBILI, N ;

MAGGIONI, D ;

TRAVERSARI, C ;

GIAVAZZI, R ;

SERVIDA, P ;

ZAPPONE, E ;

BENAZZI, E ;

BERNARDI, M ;

PORTA, F ;

FERRARI, G ;

MAVILIO, F ;

ROSSINI, S ;

BLAESE, RM ;

CANDOTTI, F .

HUMAN GENE THERAPY, 1995, 6 (06) :813-819

[6]

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].

Brentjens, Renier J. ;

Davila, Marco L. ;

Riviere, Isabelle ;

Park, Jae ;

Wang, Xiuyan ;

Cowell, Lindsay G. ;

Bartido, Shirley ;

Stefanski, Jolanta ;

Taylor, Clare ;

Olszewska, Malgorzata ;

Borquez-Ojeda, Oriana ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Bernal, Yvette ;

Rijo, Ivelise V. ;

Hedvat, Cyrus ;

Kobos, Rachel ;

Curran, Kevin ;

Steinherz, Peter ;

Jurcic, Joseph ;

Rosenblat, Todd ;

Maslak, Peter ;

Frattini, Mark ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)

[7]

Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia [J].

Buie, Larry W. ;

Pecoraro, Joshua J. ;

Horvat, Troy Z. ;

Daley, Ryan J. .

ANNALS OF PHARMACOTHERAPY, 2015, 49 (09) :1057-1067

[8]

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells [J].

Cameron, Brian J. ;

Gerry, Andrew B. ;

Dukes, Joseph ;

Harper, Jane V. ;

Kannan, Vivekanandan ;

Bianchi, Frayne C. ;

Grand, Francis ;

Brewer, Joanna E. ;

Gupta, Minnal ;

Plesa, Gabriela ;

Bossi, Giovanna ;

Vuidepot, Annelise ;

Powlesland, Alex S. ;

Legg, Alison ;

Adams, Katherine J. ;

Bennett, Alan D. ;

Pumphrey, Nicholas J. ;

Williams, Daniel D. ;

Binder-Scholl, Gwendolyn ;

Kulikovskaya, Irina ;

Levine, Bruce L. ;

Riley, James L. ;

Varela-Rohena, Angel ;

Stadtmauer, Edward A. ;

Rapoport, Aaron P. ;

Linette, Gerald P. ;

June, Carl H. ;

Hassan, Namir J. ;

Kalos, Michael ;

Jakobsen, Bent K. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (197)

[9]

Overcoming the toxicity hurdles of genetically targeted T cells [J].

Casucci, Monica ;

Hawkins, Robert E. ;

Dotti, Gianpietro ;

Bondanza, Attilio .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (01) :123-130

[10]

Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence [J].

Cavalieri, S ;

Cazzaniga, S ;

Geuna, M ;

Magnani, Z ;

Bordignon, C ;

Naldini, L ;

Bonini, C .

BLOOD, 2003, 102 (02) :497-505

← 1 2 3 4 5 6 7 8 →